Conflicts of interest in medical research: how much conflict should exceed legal boundaries?
This article addresses the current plague of financially conflicted research from various perspectives including the research community, the medical community, patients/subjects, the Food and Drug Administration (F.D.A.), and other government agencies. Part one lays out the current conflicts of interest within medical research. Part two explains the actual and potential effects of these conflicts, highlighting the conflict of interest associated with the death of Jesse Gelsinger. Part three describes how conflicts of interest are currently regulated by government agencies and within individual institutions. Lastly, part four concludes by recommending a system of seven balanced reform measures that protect research subjects and the scientific integrity of medical research while encouraging scientific progress.
Klanica
Kaley
K
Boston University School of Public Health, USA.
D035843:Biomedical Research / Q000191:economics* / Q000331:legislation & jurisprudence*; D002986:Clinical Trials as Topic / Q000009:adverse effects / Q000191:economics*; D016265:Conflict of Interest / Q000191:economics* / Q000331:legislation & jurisprudence*; D030881:Disclosure / Q000331:legislation & jurisprudence / Q000592:standards; D004345:Drug Industry / Q000191:economics*; D033161:Government Regulation; D006805:Human Experimentation / Q000331:legislation & jurisprudence / Q000592:standards*; D006801:Humans; D007258:Informed Consent / Q000592:standards; D009316:National Institutes of Health (U.S.); D012108:Research Personnel / Q000191:economics*; D035842:Research Subjects; D012109:Research Support as Topic; D014481:United States; D014486:United States Food and Drug Administration; D014495:Universities / Q000191:economics